One Quality Place Edison, NJ 08820 732-906-6155 Visit: The Interrelationship.

Slides:

Advertisements

Similar presentations

Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.

Advertisements

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

Every Solution Consultancy ISO 9001:2008 Certification Web:

1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

Ensuring Physical Stability of Pharmaceuticals: Can/should we improve our ability to identify and prevent physical changes? Ajaz S. Hussain, Ph.D. Deputy.

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

© 2001 STAT-A-MATRIX, All Rights Reserved Brazil Presentation November 27, One Quality Place Edison, New Jersey One Quality Place Edison, New Jersey.

Chapter 1 Introduction to Course and HACCP. Objective In this module, you will learn the: u Objective of the course u Format of the course u Expectations.

PILOT PROJECT: External audit of quality assurance system on HEIs Agency for Science and Higher Education Zagreb, October 2007.

Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.

PRESENTATION  Training, Facilitation & Consultation organisation  Mission:  To inspire a million lives  To make a permanent difference to.

D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Overview and Objectives Ajaz S. Hussain,

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

1 Bioequivalence of Highly Variable Drugs: Regulatory Perspectives Sam H. Haidar, R.Ph., Ph.D. Pharmacometrics Office of Generic Drugs.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Office of Process Simplification May 20, 2009 Planning an Improvement Project.

1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.

Office of Pharmaceutical Sciences

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Opening Remarks Ajaz S. Hussain, Ph.D.

Quality Management.

Do entrepreneurs cause entrepreneurship?. ENTREPRENEURship Market opportunities, technology changes, etc. play roles in entrepreneurship The entrepreneur.

PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Compliance Promotion Formalizing an Approach to Support Stakeholder Compliance.

Chapter Sixteen Control: Techniques for Enhancing Organizational Effectiveness.

10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.

QUALITY IMPROVEMENT IN PRIMARY CARE

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

Workshop For Reviewers Operating the Developmental Engagements Prof. Dr. Hala SalahProf. Dr. Hoda ELTalawy.

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.

Lean Six Sigma Data….. LeanSixSigma: Global Initiative We will come together in the next phase of Company’s growth to achieve superior value for our.

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Topic #2: Quality by Design and Pharmaceutical Equivalence Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.

Frameworks for Organizational Quality 1 Chee-Cheng Chen Dec.,

The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.

References: Supply Chain Saves the World. Boston, MA: AMR Research (2006); Designing and Managing the Supply Chain – Concepts, Strategies and Case Studies;

© 2014 GS1 US ALL RIGHTS RESERVED Making a Difference 1.

DRIVING IMPROVEMENTS Through Six MahindraSatyam

The Interrelationship between PAT and Six Sigma

Quality System.

ISCOM 472 NERD Education for Service- -iscom472nerd.com.

The Interrelationship between PAT and Six Sigma

QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.

An Introduction to the Problem Solving Process

An Introduction to the Problem Solving Process

ICH Q9: Quality Risk Management

ICH Q9: Quality Risk Management

Dr Manisha Shridhar Regional Advisor WHO-SEARO

Six Sigma Introduction 1 1.

Presentation transcript:

One Quality Place Edison, NJ Visit: The Interrelationship between PAT and Six Sigma Presented by Dr. Stanley A. Marash, P.E. Chairman and CEO STAT-A-MATRIX/The SAM Group Food and Drug Administration - PAT Pharmaceutical Science Advisory Committee Meeting October 21-23, 2002

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 2 Motivation  Significant potential and need exists for improving the efficiencies of pharmaceutical manufacturing and associated regulatory processes (Dr. Ajaz S. Hussain - May 8, 2002)

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 3 PAT  Technological opportunities (e.g. PAT) available for realizing this potential–but industry reluctant due to regulatory uncertainties (Dr. Hussain)

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 4 Six Sigma  Many aspects of the industry have adopted Six Sigma. Both PAT and 6  are process oriented approaches to achieving efficiencies, reduced cycle time and improved quality

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 5 Why PAT?  PAT provides an opportunity to move from the current “testing to document quality” paradigm to a “continuous quality assurance” paradigm that can improve our ability to ensure quality was “built-in” or was “by design” – ultimate realization of the true spirit of cGMP. (Dr. Hussain)

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 6 Why Six Sigma? DefineMeasureAnalyzeDesignVerify DefineMeasureAnalyzeImproveControl  Six Sigma embraces both continuous improvement and breakthrough performance. The process includes models for manufacturing, design and administrative services Design For Six Sigma (DFSS) Manufacturing & Administrative

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 7 Goals and Objectives  Using PAT as a model technological opportunity, develop a regulatory framework to facilitate introduction of new manufacturing technologies that enhance process efficiencies and understanding Identify and eliminate perceived/real regulatory hurdles Develop a dynamic, team based, scientific approach for regulatory assessment…of new technologies (Dr. Hussain)

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 8 PAT  Can PAT win the industry’s confidence or are the perceived/real “regulatory hurdles” too difficult to overcome?

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev. 1 9 Six Sigma  Does Six Sigma have the advantage of: No (or less) regulatory constraints Perception of an industry program not an agency program

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev Fusion Management TM  A tool for fusing PAT and Six Sigma to overcome the existing constraints

© 2002 STAT-A-MATRIX, All Rights Reserved #5147 FMOQ Rev For More Information Visit Our Web Site At: